Syndax Pharmaceuticals vs Stoke Therapeutics
Stoke Therapeutics reported revenue of $184 million in fiscal 2025, about the same as Syndax Pharmaceuticals' $172 million in fiscal 2025. Syndax Pharmaceuticals' revenue grew 627.8% in its latest year, and Stoke Therapeutics' grew 404.5%. Syndax Pharmaceuticals had an operating margin of -158.4%, against -11.2% at Stoke Therapeutics. Free cash flow was −$323 million at Syndax Pharmaceuticals and $45 million at Stoke Therapeutics.
Side by side
| Syndax Pharmaceuticals | Stoke Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $172M | $184M |
| Revenue growth | 627.8% | 404.5% |
| Revenue growth a year, last 5 years | 158.3% | — |
| Gross margin | — | — |
| Operating margin | −158.4% | −11.2% |
| Net margin | −165.6% | −3.7% |
| Free cash flow | −$323M | $45M |
| Free cash flow margin | −187.5% | 24.4% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 1.2% | 9.7% |
| Last close | $9.45 | $26.68 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $2.7 million | sold $8.7 million |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Syndax PharmaceuticalsStoke Therapeutics
Operating margin
Percent of revenue
Syndax PharmaceuticalsStoke Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Syndax PharmaceuticalsStoke Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Syndax Pharmaceuticals and Stoke Therapeutics pages.